LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment

Pietrini, Francesco; Spadafora, M.; Tatini, Lorenzo; Talamba, Gabriela Alina; Andrisano, Costanza; Boncompagni, Giancarlo; Manetti, Mara; Ricca, Valdo; Ballerini, Andrea

doi:10.1016/j.eurpsy.2016.05.008

Cited by 12 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, in our previous mirror [35] and case-control [36] studies, we found significant improvements of patients’ attitude towards treatment after 6-month of LAI antipsychotic treatment. At the same time, during the LAI-FE study, we recognized the importance of investigating the subjective experience of AMT over longer periods of time, in order to address different real-world situations.…”

Section: Introductionmentioning

confidence: 54%

“…The abovementioned results suggest the switch to LAI-AMT as a possible optimization strategy for schizophrenic patients who already achieved clinical stabilization with oral antipsychotics [25, 29, 30, 33, 35, 36], as well as encourage an early evaluation of LAI SGA use in recently diagnosed patients [8, 11, 12, 42].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, SGA-LAIs seem to be associated with better subjective experience compared to first-generation depot formulations [24,25]. Although patients' attitude towards LAIs before their use is often influenced by negative beliefs about this formulation [26][27][28], only a few studies evaluated the impact of switching to a SGA-LAI on PROs [29][30][31][32][33][34][35][36]. In this regard, our LAI-FE study (LAIs on Functioning and Experience), ongoing at the University of Florence, provided some evidence of an improved subjective experience with SGA-LAIs in the shortterm [35,36].…”

Section: Introductionmentioning

confidence: 99%

“…Although patients' attitude towards LAIs before their use is often influenced by negative beliefs about this formulation [26][27][28], only a few studies evaluated the impact of switching to a SGA-LAI on PROs [29][30][31][32][33][34][35][36]. In this regard, our LAI-FE study (LAIs on Functioning and Experience), ongoing at the University of Florence, provided some evidence of an improved subjective experience with SGA-LAIs in the shortterm [35,36]. Such lower propensity of LAI antipsychotic formulations to cause adverse subjective experiences could be due to their peculiar pharmacokinetic and pharmacodynamic characteristics (they allow to control titration to effective dose, to steady plasma drug levels, to avoid first-pass metabolism and to guarantee delivery of medication [7,8]), as well as to other individual and environmental treatment-related factors (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

Pietrini¹,

D’Anna

Tatini

et al. 2018

Eur. psychiatr.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

Pietrini¹,

D’Anna

Tatini

et al. 2018

Eur. psychiatr.

View full text Add to dashboard Cite

show abstract

“…SGA LAIs are likely to fit well into the long-term, comprehensive, multimodal treatment plans that are recommended today for schizophrenia in Italy and in other countries 23. Linking the use of SGA LAIs to the goals of patients and caregivers may contribute significantly to achieving remission and recovery 24,25. In this regard, previous evidence suggests that the use of SGA LAIs is an optimal strategy to address the subjective core of a satisfying recovery from schizophrenia.…”

Section: Introductionmentioning

confidence: 98%

<p>The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia</p>

Pietrini¹,

Albert²,

Ballerini³

et al. 2019

NDT

View full text Add to dashboard Cite

Schizophrenia is a chronic syndrome involving different clinical dimensions, and causes significant disability with a negative impact on the quality of life of patients and their caregivers. Current guidelines for the treatment of schizophrenia focus on maximizing a patient’s adaptive functioning and quality of life in a recovery-oriented approach that encourages active collaboration among patients, caregivers, and mental health professionals to design and manage a customized and comprehensive care plan. In the present study, a panel of experts (psychiatrists, psychologists, nurse, and social worker) gathered to review and explore the need for contemporary use of second-generation antipsychotic long-acting injectables (SGA LAIs) in “recovery-oriented” and “patient-centered” care of schizophrenia. Starting from the available data and from sharing personal attitudes and experiences, the panel selected three clinical dimensions considered useful in characterizing each patient: phase of disease, adherence to treatment, and level of functioning. For each clinical dimension, perspectives of patients and caregivers with regard to needs, expectations, and personal experiences were reviewed and the role of SGA LAIs in achieving shared goals examined. The experts concluded that from today’s modern perspectives, SGA-LAIs may play an important role in breaking the spiral of desocialization and functional decline in schizophrenia, thus favoring the recovery process.

show abstract

Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial

et al. 2018

View full text Add to dashboard Cite

Clinical practice guidelines recommend antipsychotic monotherapy, including oral and longacting formulations, in treatment of schizophrenia. This open-label, randomized, controlled trial is aimed to evaluate the efficacy and tolerability in patients with schizophrenia of once-monthly long-acting paliperidone palmitate (PP1M) compared with oral paliperidone extended release (ER), with a particular focus on satisfaction, subjective well-being, and service engagement. MethodSeventy-two consecutive outpatients with schizophrenia (DSM-5) were randomly assigned for six months to: (1) PP1M (50-150 mg equivalent) or (2) paliperidone ER (6-12 mg/day).Participants were assessed at baseline and after 6 months with the Treatment Satisfaction Questionnaire for Medication (TSQM); the Subjective Well-being under Neuroleptics Scale (SWN-K); the Service Engagement Scale (SES); the Clinical Global Impression-Schizophrenia (CGI-SCH); and the Personal and Social Performance (PSP) score. ANOVA repeated measures was performed. Intention to treat analysis with last observation carried forward was conducted. ResultsWe found a significant within-subjects effect (trial duration) for all rating scales, except for cognitive symptoms and the TSQM domain "side effects". A significant effect between subjects (treatment modality) was found for the CGI negative symptoms, the TSQM domains "overall satisfaction" and "convenience", and the SES. Drop-outs were 7 (9.7%): 2 due to hyperprolactinemia and 5 for the lack of compliance. ConclusionsSignificant differences between the two formulations were found. PP1M was superior to paliperidone ER on global treatment satisfaction and convenience, on service engagement, and in reducing negative symptoms.The trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) with the code: ACTRN12618001113246.

show abstract

LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment

Abstract: Our study indicates possible advantages of LAI over oral antipsychotic formulation in terms of subjective experience of maintenance treatment in remitted schizophrenic patients. Size and duration of this study need to be expanded in order to produce more solid and generalizable results.

Cited by 12 publications

References 49 publications

Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

<p>The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia</p>

Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial

Contact Info

Product

Resources

About